Overview

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-nave Participants With Active Psoriatic Arthritis

Status:
RECRUITING
Trial end date:
2028-11-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Phase:
PHASE3
Details
Lead Sponsor:
Janssen Research & Development, LLC